Abstract: A method for producing 2,5-furandicarboxylic acid (FDCA) by electrocatalytic oxidation of 5-hydroxymethylfurfural (HMF) is provided, where the catalytic oxidation is conducted using an electrolytic cell; the electrolytic cell is a three-electrode electrolytic cell or a two-electrode electrolytic cell; an anode used is a monolithic electrode; the monolithic electrode includes a carrier and a catalytically active substance loaded on the carrier; and the catalytically active substance includes cobaltosic oxide particle-encapsulated nitrogen-doped carbon nanowires. The method has high activity and high selectivity, and the anodic catalyst is highly tolerant to HMF.

Abstract: A composite polyester hot-melt adhesive, a preparation method thereof and a preparation method of an anti-scouring geotextile are provided. The preparation method of the composite polyester hot-melt adhesive includes the following steps: performing an esterification reaction on a dibasic acid and a dihydric alcohol under a protection of nitrogen and an action of a titanium/cobalt composite catalyst, adding a stabilizer for a polycondensation reaction to obtain a polyester hot-melt adhesive, then adding polymethyl methacrylate (PMMA) microspheres for mixing and stirring to obtain the composite polyester hot-melt adhesive. The anti-scouring geotextile is obtained by bonding a polyethylene terephthalate woven fabric with a polypropylene geotextile by the composite polyester hot-melt adhesive.

Abstract: The present disclosure features methods and compositions for expressing transgenes in microglia. The disclosed compositions comprise isolated fragments of human and murine translocator protein (TSPO) promoters and expression cassettes comprising the same. The methods involve using these promoters and/or expression cassettes to express transgenes in a cell.

Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.

Abstract: Resolution of a pathological condition is promoted via the application, e.g., via injection, of a potassium osmolyte such as hyperosmolar potassium gluconate, potassium aspartate, another potassium-based salt, or combinations thereof to the condition site. The application of the potassium osmolyte increases the extracellular concentration of potassium ions, reducing the membrane potential of the cells at the condition site and including immune cell quiescence. As a result, the inflammatory response in the patient to the pathological condition is reduced or eliminated. Reducing the inflammatory response is useful in treatment of myriad conditions including arthritis, auto-immune conditions, inflammatory disorders, neurodegenerative disorders, neurodevelopmental disorders, tissue breakdown, etc.

Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.

Abstract: A composition, and method for a targeted drug delivery is disclosed in treating central nervous system injury, including blast hearing loss, traumatic brain injury (TBI) and the like, by administering a subject with nanoparticle-based minocycline formulations. The formulation contains nanoparticles encapsulating minocycline for neuroprotective effect in TBI. Albumin nanoparticle-based minocycline formulations provide enhanced delivery to brain, and reduced toxicity at minimal dosage for treating a subject suffering from central nervous system injury including blast induced traumatic brain injury (bTBI). Nanoparticle administered at minimal dose in rat blast TBI model crossed blood-brain barrier (BBB) and enhanced therapeutic concentration compared to free minocycline. Provided is an effective and safe minocycline delivery in TBI with minimal or no toxicity for neuroprotective therapy.

Abstract: An electrically assisted forming process and device for a high-strength metal alloy thin-walled pipe includes a die sleeve, wiring terminals, a pulse power supply, a die seat, sealing baffle plates, a drawing die, and a cooling water circulation chamber. A process for forming a high-strength metal alloy thin-walled pipe includes first, graphite or fusible metal, i.e., an aluminum rod, is introduced into a high-strength metal alloy pipe to be drawn to fill the whole pipe; and then, pulse current is introduced into a plastic deformation area of the thin-walled pipe. A cooling device can be provided to achieve a good cooling effect. The thin-walled pipe with corresponding length is cut according to a production requirement after processing is completed, and annealing treatment is performed in a vacuum heat treatment furnace.

Abstract: One example described herein involves a system receiving task data and distribution criteria for a state space model from a client device. The task data can indicate a type of sequential Monte Carlo (SMC) task to be implemented. The distribution criteria can include an initial distribution, a transition distribution, and a measurement distribution for the state space model. The system can generate a set of program functions based on the task data and the distribution criteria. The system can then execute an SMC module to generate a distribution and a corresponding summary, where the SMC module is configured to call the set of program functions during execution of an SMC process and apply the results returned from the set of program functions in one or more subsequent steps of the SMC process. The system can then transmit an electronic communication to the client device indicating the distribution and its corresponding summary.

Abstract: The present disclosure describes compounds of the formula: (I), (II), (III), (IV), (V). The compounds described herein may be cyclooxygenase (COX) (e.g., cyclooxygenase 2 (COX2)) inhibitors. The compounds may be radiolabeled. The compounds (e.g., radiolabeled compounds) may be useful (e.g., as positron emission tomography (PET) imaging agents) for diagnosing a disease. The compounds may also be useful for treating or preventing a disease. The present disclosure also describes pharmaceutical compositions and kits including the compounds; and methods of using the compounds.

Abstract: A method for producing metabolites that are heavy alcohols, and particularly branched-chain alcohols is provided, involving contacting a suitable substrate with recombinant microorganisms. The microorganisms contain at least one deletion, disruptions, or mutations from the GLN gene family, VPS gene family, GNP gene family, AVT gene family, GCN gene family, or YDR391C, and combinations thereof, and overproduce the heavy alcohol as compared to a wild-type yeast strain.

Abstract: The present disclosure relates to a herringbone-type fluid guiding unit and an apparatus for concentrating fluid using same. The herring-bone type fluid guiding unit includes: a front member formed on a flow path and formed so that the width between the left side and the right side widens from a front end part toward the back, with respect to the flow direction of a fluid; and a rear member extending from the front member toward the back, wherein the rear member is provided with a recessed part that is recessed to a specific depth from the rear edge toward the front or with a protruding part that protrudes toward the back.

Abstract: An interference imaging device includes a light interference generator that includes: a light wave splitter configured to reflect a part of incident light and to allow a remaining part of the incident light to pass through; a phase modulator configured to modulate a phase of incident light that has passed through the light wave splitter; and a reflector configured to reflect the phase-modulated incident light from the phase modulator so that the reflected, phase-modulated incident light overlaps with incident light that has been reflected by the light wave splitter.

Abstract: A fumed silica monolithic integrating cavity device. The device is configured to facilitate optical measurements taken from a sample positioned within a cavity of the device. The cavity is defined by a fumed silica monolith with the added feature of a fused quartz lining on the surface of the monolith. This provides an intermediate surface that allows for cleaning and reuse of the highly effective diffuse light scattering fumed silica monolith. Furthermore, the lining may be placed under pressure or vacuum to structurally enhance mechanical integrity of the underlying monolith. Thus, continued or reliably repeated use of the device may be appreciated as well as use in more industrial environments that are prone to vibration.

Abstract: A method of establishing a connection for direct communication between terminals, performed in a terminal, may comprise transmitting a sensing signal or a sidelink discovery signal; transmitting sidelink discovery information; receiving a response to the sidelink discovery signal or the sidelink discovery information from a peer terminal; determining a cast type for the peer terminal, and establishing a PC5-radio resource control (RRC) connection with the peer terminal when the cast type is determined to be a unicast scheme or groupcast scheme; and performing direct communication with the peer terminal.

Abstract: The application discloses a specific ACKR2 modulator for use in the treatment of a proliferative disease or disorder in a subject and/or for use in improving the response of a subject to anticancer immunotherapy. The application further discloses pharmaceutical compositions comprising such a specific ACKR2 modulator and one or more immune checkpoint modulators, preferably one or more immune checkpoint inhibitors.

Abstract: Bispecific aptamers having a first end that specifically binds to a first tumor specific marker, tumor antigen, or viral protein and a second end that specifically binds to a second tumor specific marker, tumor antigen, or viral protein are provide. The bispecific aptamers can be used to treat cancer or virally infected cells. Generally, the bispecific aptamers bind to two surface proteins, preferably different proteins, on the same cell. In a preferred embodiment the bispecific aptamers bind to two different tumor markers, tumor antigens, tumor specific proteins and combinations thereof.

Abstract: A method for detecting on-off keying symbols includes receiving, by each of distributed Rx nodes, a pilot signal for a pilot symbol transmitted from a transmitter, the distributed Rx nodes constituting the wireless body area communication network, obtaining, by each of the Rx nodes, a reference value using the received pilot signal, transmitting, by each of the Rx nodes, received data signal to a fusion center when the data signal for the on-off keying symbol transmitted from the transmitter is received by each of the Rx nodes, calculating, by the fusion center, a weight of the on-off keying symbol for each of the Rx nodes using the reference value obtained from each of the Rx nodes and the received data signal, and detecting, by the fusion center, the on-off keying symbol transmitted from the transmitter using the weight of the on-off keying symbol calculated for each of the Rx nodes.

Abstract: Provided herein are compounds that inhibit histone lysine demethylase (KDM) and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and methods of treating or preventing diseases (e.g., proliferative diseases, e.g., cancer). In certain embodiments, the compounds described herein are represented by formulas (I) and (II).

Abstract: Provided is an X-ray tube which includes a first electrode, a second electrode spaced apart from the first electrode, a target disposed in a lower portion of the second electrode, an emitter on the first electrode, a third electrode which is positioned between the first electrode and the second electrode and includes an opening at a position perpendicularly corresponding to the emitter, and a spacer provided on the third electrode and surrounding the second electrode. The spacer includes a first section located adjacent to the third electrode and a second section disposed on the first section. The spacer includes a ceramic insulator and conductive dopants dispersed within the ceramic insulator. A concentration of the conductive dopants in the first section of the spacer is greater than a concentration of the conductive dopants in the second section. The third electrode is in contact with the first section of the spacer.